

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)Applicant/Patent Owner: Altus Pharmaceuticals, Inc.Application No./Patent No.: 09/631,241 Filed/Issue Date: 08/02/00Entitled: Controlled dissolution crosslinked protein crystalsAltus Pharmaceuticals, Inc., a Corporation
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest
(The extent (by percentage) of its ownership interest is _____ %)

in the patent application/patent identified above by virtue of either:

A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

OR

B. ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: inventor(s) To: Altus Biologics Inc.
The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.
2. From: Altus Biologics Inc. To: Altus Pharmaceuticals, Inc.
The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.
3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☒ As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

<u>/Natalie A. Lissy/</u>	<u>04/24/08</u>
Signature	Date
<u>Natalie A. Lissy</u>	<u>617-395-7000</u>
Printed or Typed Name	Telephone Number
<u>Patent Attorney</u>	
Title	

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (*i.e.*, GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

A S S I G N M E N T

We,

- (1) ALEXEY L. MARGOLIN,
- (2) ROSE A. PERSICHETTI,
- (3) NANCY L. ST. CLAIR,

and

- (4) NAZER K. KHALAF

residing, respectively, at

- (1) 19 Upland Avenue, Newton, Massachusetts 02161,
- (2) 375 Harvard Road, Stow, Massachusetts 01775,
- (3) 806 East Forest Hill Boulevard, Durham, North Carolina 27707,

and

- (4) 14 Lauf Street, Worcester, Massachusetts 01602

for good and valuable consideration, receipt of which is hereby acknowledged, have assigned, sold and transferred to and do hereby assign, sell and transfer to ALTUS BIOLOGICS INC., a corporation organized under the laws of the Commonwealth of Massachusetts and having an office and place of business at 40 Allston Street, Cambridge, Massachusetts (U.S.A.) 02139-4211, its successors and assigns: (1) the entire right, title and interest in the United States and in and to any and all our inventions and discoveries disclosed in the application for Letters Patent in the United States entitled:

CONTROLLED DISSOLUTION CROSSLINKED PROTEIN CRYSTALS, and filed in the United States Patent and Trademark Office on April 11, 1997, under Serial Number 08/834,661, including any renewals, revivals, reissues, reexaminations, extensions, continuations and divisions thereof, and any substitute applications therefor; (2) the full and complete

right to file patent applications in the name of ALTUS BIOLOGICS INC., its designee, or in our names at ALTUS BIOLOGICS INC.'s or its designee's election, on the aforesaid inventions, discoveries and applications in the United States; (3) the entire right, title and interest in and to any Letters Patent which may issue thereon in the United States and any renewals, revivals, reissues, reexaminations and extensions of the same; and (4) the entire right, title and interest in all Convention and Treaty Rights of all kinds thereon, including without limitation all rights of priority in the United States, in and to the above inventions, discoveries and applications.

We hereby authorize and request the competent authorities to grant and to issue any and all such Letters Patent in the United States to ALTUS BIOLOGICS INC. as the assignee of the entire right, title and interest therein, as fully and entirely as the same would have been held and enjoyed by us had this assignment, sale and transfer not been made.

We agree, at any time, upon the request of ALTUS BIOLOGICS INC. to execute and to deliver to ALTUS BIOLOGICS INC. any additional applications for patents for said inventions and discoveries, or any part or parts thereof, and any applications for patents of confirmation, registration and importation based on any Letters Patent issuing on said inventions, discoveries or applications, and divisions, continuations, renewals, revivals, reissues, reexaminations and extensions thereof.

We further agree at any time to execute and to deliver upon request of ALTUS BIOLOGICS INC. such additional documents, if any, as are necessary or desirable to secure patent protection on said inventions, discoveries and applications in the United States, and otherwise to do the necessary to give full effect to and to perfect the rights of ALTUS BIOLOGICS INC. under this Assignment, including the execution, delivery and procurement of any

and all further documents evidencing this assignment,
transfer and sale as may be necessary or desirable.

ASSIGNOR:

Alexey L. Margolin (1)
ALEXEY L. MARGOLIN

On this 11 day of November, 1997
Alexey L. Margolin (1)
personally appeared before me, a Notary Public in and for
Massachusetts,
and executed the foregoing Assignment and duly acknowledged
to me that such Assignment was executed for the uses and
purposes therein expressed.

Sarah P. Cecil
Notary Public

(Notarial seal)

My Commission Expires:

3/30/01

ASSIGNOR:

Rose A. Persichetti (2)
ROSE A. PERSICHETTI

On this 11th day of November, 1997
Rose A. Persichetti (2)
personally appeared before me, a Notary Public in and for
Massachusetts,
and executed the foregoing Assignment and duly acknowledged
to me that such Assignment was executed for the uses and
purposes therein expressed.

Samah P. Cecil
Notary Public

(Notarial seal)

My Commission Expires:

3/30/01

ASSIGNOR:

Nancy L. St. Clair (3)
NANCY L. ST. CLAIR

On this 3 day of November, 1997
Nancy L. St. Clair (3)
personally appeared before me, a Notary Public in and for
Cumberland County,
and executed the foregoing Assignment and duly acknowledged
to me that such Assignment was executed for the uses and
purposes therein expressed.


Thomas J. Poud
Notary Public

(Notarial seal)

My Commission Expires:

9-19-99

ASSIGNOR:



NAZER K. KHALAF (4)

On this 11th day of November, 1997
Nazer K. Khalaf (4)
personally appeared before me, a Notary Public in and for
Massachusetts,
and executed the foregoing Assignment and duly acknowledged
to me that such Assignment was executed for the uses and
purposes therein expressed.



Notary Public

(Notarial seal)


My Commission Expires:

3/30/01

ACKNOWLEDGEMENT OF ASSIGNEE:

I hereby acknowledge the foregoing executed Assignment on
behalf of ALTUS BIOLOGICS INC.

ALTUS BIOLOGICS INC.

By 

Peter Lanciano
President

Signed at: Cambridge, Massachusetts (U.S.A.)

on 11/11/97, 1997

Delaware

PAGE 1


The First State

I, HARRIET SMITH WINDSOR, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THAT THE SAID "ALTUS BIOLOGICS, INC.", FILED A RESTATED CERTIFICATE, CHANGING ITS NAME TO "ALTUS PHARMACEUTICALS INC.", THE TWENTIETH DAY OF MAY, A.D. 2004, AT 9:58 O'CLOCK A.M.

AND I DO HEREBY FURTHER CERTIFY THAT THE AFORESAID CORPORATION IS DULY INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE AND IS IN GOOD STANDING AND HAS A LEGAL CORPORATE EXISTENCE NOT HAVING BEEN CANCELLED OR DISSOLVED SO FAR AS THE RECORDS OF THIS OFFICE SHOW AND IS DULY AUTHORIZED TO TRANSACT BUSINESS.

AND I DO HEREBY FURTHER CERTIFY THAT THE FRANCHISE TAXES HAVE BEEN PAID TO DATE.

AND I DO HEREBY FURTHER CERTIFY THAT THE ANNUAL REPORTS HAVE BEEN FILED TO DATE.



Harriet Smith Windsor
Harriet Smith Windsor, Secretary of State

3427145 8320

060079566

AUTHENTICATION: 4480518

DATE: 01-26-06